Skip to main content
OpenTrials
Completed

NCT Number: NCT04925453

tDCS and Cognitive Training in Active Duty Service Members With Mild TBI: A Pilot Study

The proposed study will evaluate a new approach to cognitive rehabilitation of mild traumatic brain injury (mTBI) using a brain stimulation technique called transcranial direct current stimulation (tDCS). Specifically, we will investigate how tDCS combined with cognitive training improves deficits to attention and working memory in Active Duty Service Members with a history of mild traumatic brain injury (TBI). Measures of attention-related brain activity, neurocognitive assessments, and self-reported clinical outcomes will be used to determine effects of tDCS vs. sham tDCS when paired with a cognitive training intervention. By doing this study, we hope to find a reliable, noninvasive, and efficient method of treating mild TBI cognitive symptoms.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Brain Concussion Attention Concentration Difficulty Attention Impaired Brain Diseases Brain Injuries Brain Injuries, Traumatic Brain Trauma Central Nervous System Diseases Cognition Disorders Cognitive Dysfunction Craniocerebral Trauma Head Injuries, Closed Memory Disorders Memory Impairment Mental Disorders Mild Cognitive Impairment Mild Traumatic Brain Injury Nervous System Diseases Neurobehavioral Manifestations Neurocognitive Disorders Neurocognitive Dysfunction Neurologic Manifestations Pathological Conditions, Signs and Symptoms Signs and Symptoms Trauma, Nervous System Wounds and Injuries Wounds, Nonpenetrating

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Naval Medical Center San Diego

San Diego, California, 92134, United States

About this study

Objectives: The proposed study will evaluate a new approach to cognitive rehabilitation of mild traumatic brain injury (mTBI) using a brain stimulation technique called transcranial direct current stimulation (tDCS). Specifically, we will investigate how tDCS combined with cognitive training improves deficits to attention and working memory in Active Duty Service Members with a history of mTBI. Measures of attention-related brain activity, neurocognitive assessments, and self-reported clinical outcomes will be used to determine effects of tDCS vs. sham tDCS when paired with a cognitive training intervention. By doing this study, we hope to find a reliable, noninvasive, and efficient method of treating mild TBI cognitive symptoms.

Research Plan and Methods: This is a double-blind, randomized, placebo (sham) controlled pilot study. We will recruit 60 Active Duty Service Members who are receiving outpatient services at Naval Medical Center San Diego, with a history of mTBI and reported neurocognitive symptoms related to attention, working memory, and related cognitive processes. Intake will involve a full pre-assessment of symptoms, neurocognitive performance, and an optional MRI scan. Participants will be randomized to either active or sham tDCS. Training/tDCS sessions will occur daily over five consecutive days. Random permuted blocks will be used to ensure exactly equal treatment numbers at certain equally spaced points in the sequence of patient assignment. Post-intervention assessment will include another assessment of symptoms, neurocognitive performance, and an optional MRI scan. Participants will complete assessments of symptoms and neurocognitive performance six-weeks following the post-intervention assessment.

Clinical Relevance to TBICoE/Navy Medicine: Aspects of this study will provide insight into a major research gap highlighted in the mission of the Defense and Veterans Brain Injury Center, specifically in identifying/ developing innovative treatments/interventions which promote patient recovery and/or mitigate symptoms after mTBI. Novel, well-tolerated, neuroplasticity-based interventions that can improve attention, concentration, and working memory by targeting the underlying neural dysfunction are needed to improve outcomes and quality of life for Active Duty Service Members affected by neurocognitive weakness and dysfunction following mTBI. If tDCS proves successful in reducing TBI-related symptoms, improving cognition, or enhancing functional recovery, this non-invasive intervention could be implemented within various DoD and VA settings, enhancing recovery, improving quality of life, and bolstering occupational performance.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • (1) Have a remote history mild traumatic brain injury as defined by the VA/DoD clinical practice guidelines(The Management of Concussion/mTBI Working Group, 2016) that is >/= 6 months, and report moderate severity neurocognitive symptoms related to attention, concentration, working memory, or memory based on NSI scores and self-report.
  • (2) Are between the ages of 18-55.
  • (3) Are stable on any medications for at least 2 weeks at the baseline visit (Visit #1).

Exclusion criteria

  • (1) Have a history of seizures or epilepsy.
  • (2) Have a history of ECT or cortical energy exposure within the past 12 months, including participation in any other neuromodulation studies.
  • (3) Have current stimulant dependence.
  • (4) Have a diagnosis of intellectual disability or pervasive developmental disorder (i.e. premorbid IQ less than or equal to 70).
  • (5) Have any medical condition or treatment other than mild TBI (e.g. stroke, tumor, HIV, moderate-severe TBI), with significant neurological disorder or insults that, based on the Principal Investigator's judgement, would impact risk.
  • (6) Diagnosed with current active psychosis or mania.
  • (7) Have metallic cranial plates/screws or implanted device,
  • (8) Have eczema on scalp or other scalp lesions or skin disorders that may become irritated by stimulation.
  • (9) Pregnant individuals and individuals with ferromagnetic metal in their body that would prohibit them from being safe in the MRI will not be excluded from the overall study, but will be excluded from the optional MRI.

Treatment and study plan

Active tDCS and Cognitive Training Intervention

Combination Product

Intervention sessions will occur during Visits 2-6. Cognitive training will occur concurrently with tDCS in both the active and sham tDCS groups. Over each 46-minute daily training period, 4 of 5 BrainHQ training tasks will be performed for approximately 11 minutes in a randomly selected order. Order of task presentation will be randomized each session. Stimulation sequences will occur in the first 13 minutes (shut off: Minute 13) of the session and the last 13 minutes of the session (turn on: Minute 33). The Symptom Rating Questionnaire (SRQ) will be asked before and after stimulation to assess for any side-effects. The BrainHQ Task Load Index (TLX) will be administered at the end of each intervention session. At the end of Intervention Session 3, subjects will be given a Blinding Questionnaire which asks whether they thought they received active or sham treatment.

Other names: intervention group, active group

Sham tDCS and Cognitive Training Intervention

Combination Product

Intervention sessions will occur during Visits 2-6. Cognitive training will occur concurrently with tDCS in both the active and sham tDCS groups. Over each 46-minute daily training period, 4 of 5 BrainHQ training tasks will be performed for approximately 11 minutes in a randomly selected order. Order of task presentation will be randomized each session. Stimulation sequences will occur in the first and last 13 minutes of the session. For sham stimulation, the electrodes will be placed at the same positions as for active stimulation, but current will be ramped down immediately after the initial 30s ramp up period. The Symptom Rating Questionnaire (SRQ) will be asked before and after stimulation to assess for any side-effects. The BrainHQ Task Load Index (TLX) will be administered at the end of each intervention session. At the end of Intervention Session 3, subjects will be given a Blinding Questionnaire which asks whether they thought they received active or sham treatment.

Other names: fake tDCS group, placebo group, sham group

Primary outcomes

  1. Symbol Digit Modalities Test (SDMT)

    Time frame: Change from Baseline SDMT at 1 week after the intervention.

    Standardized neuropsychological assessment measure of visual attention and working memory

  2. Symbol Digit Modalities Test (SDMT)

    Time frame: Change from Baseline SDMT at 6 weeks after the intervention.

    Standardized neuropsychological assessment measure of visual attention and working memory

  3. Symbol Digit Modalities Test (SDMT)

    Time frame: Change from 1 week post-intervention SDMT at 6 weeks after the intervention.

    Standardized neuropsychological assessment measure of visual attention and working memory

  4. Neuropsychological Assessment Battery (NAB) Attention Module

    Time frame: Change from Baseline NAB Attention Module at 1 week after the intervention.

    Standardized neuropsychological assessment consisting of 4 subtests to assess visual and auditory attention, working memory, and scanning.

  5. Neuropsychological Assessment Battery (NAB) Attention Module

    Time frame: Change from Baseline NAB Attention Module at 6 weeks after the intervention.

    Standardized neuropsychological assessment consisting of 4 subtests to assess visual and auditory attention, working memory, and scanning.

  6. Neuropsychological Assessment Battery (NAB) Attention Module

    Time frame: Change from 1 week post-intervention NAB Attention Module at 6 weeks after the intervention.

    Standardized neuropsychological assessment consisting of 4 subtests to assess visual and auditory attention, working memory, and scanning.

  7. Electroencephalogram (EEG)

    Time frame: Change from Baseline EEG at 1 week after the intervention.

    EEG will be collected to assess neural dynamics during rest and during performance of generalization tasks. The neural dynamics to be assessed include functional connectivity, mean ERP amplitude, and spectral power of delta, theta, alpha, beta, and gamma frequency bands.

  8. Electroencephalogram (EEG)

    Time frame: Change from Baseline EEG at 6 weeks after the intervention.

    EEG will be collected to assess neural dynamics during rest and during performance of generalization tasks. The neural dynamics to be assessed include functional connectivity, mean ERP amplitude, and spectral power of delta, theta, alpha, beta, and gamma frequency bands.

  9. Electroencephalogram (EEG)

    Time frame: Change from 1 week post-intervention EEG at 6 weeks after the intervention.

    EEG will be collected to assess neural dynamics during rest and during performance of generalization tasks. The neural dynamics to be assessed include functional connectivity, mean ERP amplitude, and spectral power of delta, theta, alpha, beta, and gamma frequency bands.

  10. Neurobehavioral Symptom Inventory (NSI)

    Time frame: Change from Baseline NSI at 1 week after the intervention.

    A measure of common post-concussive symptoms rated on a 5-point Likert scale (0-4); with low scores corresponding to mild or no incidence of symptoms and high scores corresponding to more severe incidence of symptoms.

  11. Neurobehavioral Symptom Inventory (NSI)

    Time frame: Change from Baseline NSI at 6 weeks after the intervention.

    A measure of common post-concussive symptoms rated on a 5-point Likert scale (0-4); with low scores corresponding to mild or no incidence of symptoms and high scores corresponding to more severe incidence of symptoms.

  12. Neurobehavioral Symptom Inventory (NSI)

    Time frame: Change from 1 week post-intervention NSI at 6 weeks after the intervention.

    A measure of common post-concussive symptoms rated on a 5-point Likert scale (0-4); with low scores corresponding to mild or no incidence of symptoms and high scores corresponding to more severe incidence of symptoms.

  13. Magnetic Resonance Imaging (MRI) w/out contrast (optional)

    Time frame: Change from Baseline MRI at 1 week after the intervention.

    Medical imaging technique that uses a magnetic field and computer-generated radio waves to create detailed images of the organs and tissues in your body. Mean white matter and CSF signals across time are calculated for each participant. Additionally, time courses for regions of interest are also extracted.

Secondary outcomes

  1. NIH Toolbox Quality of Life Assessment (NeuroQoL)

    Time frame: Change from Baseline NeuroQoL at 1 week after the intervention.

    Questionnaire to assess quality of life with regard to cognitive, social, emotional, and behavioral abilities rated on a 5-point Likert scale (1-5); with low scores corresponding to mild to no impairment in these abilities and high scores corresponding to more severe impairment in these abilities.

  2. NIH Toolbox Quality of Life Assessment (NeuroQoL)

    Time frame: Change from Baseline NeuroQoL at 6 weeks after the intervention.

    Questionnaire to assess quality of life with regard to cognitive, social, emotional, and behavioral abilities rated on a 5-point Likert scale (1-5); with low scores corresponding to mild to no impairment in these abilities and high scores corresponding to more severe impairment in these abilities.

  3. NIH Toolbox Quality of Life Assessment (NeuroQoL)

    Time frame: Change from 1 week post-intervention NeuroQoL at 6 weeks after the intervention.

    Questionnaire to assess quality of life with regard to cognitive, social, emotional, and behavioral abilities rated on a 5-point Likert scale (1-5); with low scores corresponding to mild to no impairment in these abilities and high scores corresponding to more severe impairment in these abilities.

  4. Insomnia Severity Index (ISI)

    Time frame: Change from Baseline ISI at 1 week after the intervention.

    Measure of insomnia severity rated on a 5-point Likert scale (0-4); with low scores corresponding to mild or no incidence of insomnia and high scores corresponding to more severe incidences of insomnia.

  5. Insomnia Severity Index (ISI)

    Time frame: Change from Baseline ISI at 6 weeks after the intervention.

    Measure of insomnia severity rated on a 5-point Likert scale (0-4); with low scores corresponding to mild or no incidence of insomnia and high scores corresponding to more severe incidences of insomnia.

  6. Insomnia Severity Index (ISI)

    Time frame: Change from 1 week post-intervention ISI at 6 weeks after the intervention.

    Measure of insomnia severity rated on a 5-point Likert scale (0-4); with low scores corresponding to mild or no incidence of insomnia and high scores corresponding to more severe incidences of insomnia.

  7. Fusion Task

    Time frame: Change from Baseline Fusion task at 1 week after the intervention.

    Multi-modal assessment of brain function including EEG and eye tracking. The EEG measures to be assessed include functional connectivity, mean ERP amplitude, and spectral power of delta, theta, alpha, beta, and gamma frequency bands. Other outcome measures to be assessed include saccadic response time latency, saccadic response time consistency, manual response time latency, manual response time consistency, and 1-back total score.

  8. Fusion Task

    Time frame: Change from Baseline Fusion task at 6 weeks after the intervention.

    Multi-modal assessment of brain function including EEG and eye tracking. The EEG measures to be assessed include functional connectivity, mean ERP amplitude, and spectral power of delta, theta, alpha, beta, and gamma frequency bands. Other outcome measures to be assessed include saccadic response time latency, saccadic response time consistency, manual response time latency, manual response time consistency, and 1-back total score.

  9. Fusion Task

    Time frame: Change from 1 week post-intervention Fusion task at 6 weeks after the intervention.

    Multi-modal assessment of brain function including EEG and eye tracking. The EEG measures to be assessed include functional connectivity, mean ERP amplitude, and spectral power of delta, theta, alpha, beta, and gamma frequency bands. Other outcome measures to be assessed include saccadic response time latency, saccadic response time consistency, manual response time latency, manual response time consistency, and 1-back total score.

  10. tDCS Symptom Rating Questionnaire (SRQ)

    Time frame: Change from pre-intervention SRQ at post-intervention.

    Questionnaire to assess pre-post tDCS symptom rating, rated on a 4-point Likert scale (0-3); with low scores corresponding to mild or no incidence of symptoms and high scores corresponding to severe incidence of symptoms.

  11. BrainHQ Task Load Index (TLX)

    Time frame: Immediately after the intervention.

    Subjective workload assessment of level of effort, mental demand, frustration, and performance during cognitive training, rated on a 10-point Likert scale (1-10); with low scores corresponding to less effort or mental demand and high scores corresponding to more effort or mental demand.

Sponsors and collaborators

Lead sponsor

United States Naval Medical Center, San Diego

Fed

Collaborators

  • The Defense and Veterans Brain Injury Center

Registry information

Official study title

Transcranial Direct Current Stimulation (tDCS) and Cognitive Training to Improve Concentration and Working Memory in Active Duty Service Members Following Mild Traumatic Brain Injury (mTBI): A Pilot Study

Important dates

Study start
2021
Primary completion
2025
Study completion
2025
First posted
Jun 14, 2021
Registry last updated
Nov 12, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.